Effects of growth hormone treatment in children presenting with prader-willi syndrome: The KIGS experience

Growth Hormone Therapy in Pediatrics 20 Years of KIGS

Volumn , Issue , 2007, Pages 377-388

  Tauber, MaÏthé ^a  

^a HÔPITAL DES ENFANTS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41849138910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000101869     Document Type: Chapter

References (19)

1. Carrel AL, Myers SE, Whitman BY, Allen DB: Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-1585.
2. Lindgren AC, Ritzen EM: Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl 1999;88:109-111.
3. Burman P, Ritzen EM, Lindgren AC: Endocrine dysfunction in Prader-Willi syndrome: a review with special refer-ence to GH. Endocr Rev 2001;22:787-799.
4. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH: Effects of growth hormone on pul-monary function, sleep quality, behav-ior, cognition, growth velocity, body composition, and resting energy expen-diture in Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88:2206-2212.
5. Lindgren AC, Hagenas L, Muller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzen EM: Growth hormone treatment of children with Prader-Willi syn-drome affects linear growth and body composition favourably. Acta Paediatr 1998;87:28-31.
6. Tauber M, Barbeau C, Jouret B, Pien-kowski C, Malzac P, Moncla A, Rochic-cioli P: Auxological and endocrine evo-lution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children. Horm Res 2000;53:279-287.
7. Eiholzer U, Schlumpf M, Nordmann Y, l'Allemand D: Early manifestations of Prader-Willi syndrome: influence of growth hormone. J Pediatr Endocrinol Metab 2001;14:1441-1444.
8. Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson-Wikland K, Ranke MB, Price DA, KIGS Interna-tional Board: Growth hormone treat-ment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178-185.
9. Prader A, Labhart A, Willi H: Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchidismus und Oligophrenie nach myotonieartigem Zustand im Neugeborenenalter. Schweiz Med Wochenschr 1956;6:1260-1261.
10. Prader A, Largo RH, Molinari L, Issler C: Physical growth from birth to 20 years of age. First Zürich longitudinal study of growth and development. Helv Paediatr Acta Suppl 1988;52:1-125.
11. Butler MG, Meaney FJ: Standards for selected anthropometric measurements in Prader-Willi syndrome. Pediatrics 1991;88:853-860.
12. Ranke MB, Lindberg A, Albertsson-Wikland K, Wilton P, Price DA, Reiter EO: Increased response, but lower re-sponsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH deficiency: analysis of data from KIGS. J Clin Endocrinol Metab 2005;90:1966-1971.
13. Gillessen-Kaesbach G, Robinson W, Lohmann D, Kaya-Westerloh S, Pas-sarge E, Horsthemke B: Genotype-phe-notype correlation in a series of 167 deletion and non-deletion patients with Prader-Willi syndrome. Hum Genet 1995;96:638-643.
14. Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F: Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin Endo-crinol (Oxf) 1998;48:769-775.
15. Cappa M, Raguso G, Palmiotto T, Faed-da A, Gurreri F, Neri G, Deghenghi R, Loche S: The growth hormone response to hexarelin in patients with Prader-Willi syndrome. J Endocrinol Invest 1998;21:501-505.
16. Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M: Growth hormone secretion and ef-fects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 1996;9:393-400.
17. Beccaria L, Bosio L, Sanzari A, Aima-retti G, Ghigo E, Chiumello G: GH se-cretion in Prader-Labhart-Willi syn-drome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine. J Pediatr Endocri-nol Metab 1996;9:577-583.
18. Eiholzer U, l'Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, Gruters A, Simoni M: Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart-Willi syn-drome. J Clin Endocrinol Metab 2006;91:892-898.
19. Crino A, Schiaffini R, Ciampalini P, Spera S, Beccaria L, Benzi F, Bosio L, Corrias A, Gargantini L, Salvatoni A, Tonini G, Trifiro G, Livieri C, Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology (SIEDP): Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr 2003;162:327-333.